- Q1 2024 Heron Therapeutics Inc Earnings Call TranscriptMay 07, 2024€2.85 (+10.71%)Earnings
- Q4 2023 Heron Therapeutics Inc Earnings Call TranscriptMar 12, 2024€2.16 (-7.69%)Earnings
- Q3 2023 Heron Therapeutics Inc Earnings Call TranscriptNov 14, 2023€0.525 (-6.25%)Earnings
- Q2 2023 Heron Therapeutics Inc Earnings Call TranscriptAug 14, 2023€1.46 (-0.68%)Earnings
- Q1 2023 Heron Therapeutics Inc Earnings Call TranscriptMay 11, 2023€2.08 (-5.45%)Earnings
- Heron Therapeutics Inc at Needham Healthcare Conference (Virtual) TranscriptApr 20, 2023
- Q4 2022 Heron Therapeutics Inc Earnings Call TranscriptMar 23, 2023€1.9 (-0.06%)Earnings
- Q3 2022 Heron Therapeutics Inc Earnings Call TranscriptNov 08, 2022€3.37 (+1.05%)Earnings
- Heron Therapeutics Inc Investor Call TranscriptSep 19, 2022
- Q2 2022 Heron Therapeutics Inc Earnings Call TranscriptAug 09, 2022€4.18 (+20.54%)Earnings
- Q1 2022 Heron Therapeutics Inc Earnings Call TranscriptMay 09, 2022€3.81 (+1.18%)Earnings
- Heron Therapeutics Inc at Needham Healthcare Conference (Virtual) TranscriptApr 11, 2022
- Q4 2021 Heron Therapeutics Inc Earnings Call TranscriptFeb 28, 2022€6.28 (-5.54%)Earnings
- Heron Therapeutics Inc Announces FDA Approval of a Significant Indication Expansion for ZYNRELEF TranscriptDec 09, 2021
- Q3 2021 Heron Therapeutics Inc Earnings Call TranscriptNov 03, 2021€9.69 (-0.23%)Earnings
- Heron Therapeutics Inc to Host U.S. FDA Approval of ZYNRELEFâ„¢ - Conference Call TranscriptMay 13, 2021
- Heron Therapeutics Inc 2020 Conference Call TranscriptJun 29, 2020
- Heron Therapeutics Inc Annual Shareholders Meeting TranscriptJun 17, 2020
- Heron Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptOct 02, 2019
- Heron Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference TranscriptMay 14, 2019
- Heron Therapeutics Inc to discuss the Complete Response Letter - Conference Call TranscriptMay 01, 2019
Heron Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Good afternoon. Thank you very much for joining us here today. Next up presenting we have Heron Therapeutics and presenting for Heron will be Barry Quart, the CEO. Heron will have a breakout session in Astor Suite 1 afterwards.
Barry, it's been a busy week for you guys with a lot of good news, so look forward to hearing your presentation. Thank you.
Thanks very much. Always a pleasure to be here. Thanks for the opportunity again. So yes, we have a lot of news the last couple days. We will certainly go through all that. Of course, start with the usual forward-looking statements.
And then just a quick reminder: the Company has two main areas of focus. One is chemotherapy-induced nausea and vomiting with two marketed products: SUSTOL and CINVANTI. We will talk a little bit about those later on.
But we will focus attention mostly on HTX-011, which we recently put out a notice that we have refiled to the FDA. We have had very good
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)